Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Suvorexant Clear all
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

NCT04706091
View directory record Official record
Conditions
Restless Legs Syndrome, Insomnia, Sleep Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547
View directory record Official record
Conditions
Sleep, Alzheimer Disease
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

NCT05593653
View directory record Official record
Conditions
Insomnia, Metabolic Health, Menopause
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 4 Interventional

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

NCT03642028
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional Results available

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

NCT06162663
View directory record Official record
Conditions
Breast Cancer, Insomnia
Interventions
Suvorexant Tablets, Placebo Control
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

NCT03312517
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant 10 mg, Suvorexant 20 mg, Placebo oral capsule
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

NCT06584942
View directory record Official record
Conditions
Cue-reactivity, Cannabis Use Disorder, Functional MRI, Orexin Antagonist
Interventions
Suvorexant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

NCT02527564
View directory record Official record
Conditions
Insomnia, Bipolar Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional

Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

NCT04287062
View directory record Official record
Conditions
Sleep Disturbance, Opioid-use Disorder
Interventions
Suvorexant, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Elkton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
View directory record Official record
Conditions
Smoking Cessation
Interventions
Suvorexant 20 mg, Suvorexant 0mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional Results available

Suvorexant in Insomnia Co-morbid With Fibromyalgia

NCT02684136
View directory record Official record
Conditions
Insomnia, Fibromyalgia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

NCT05908526
View directory record Official record
Conditions
Insomnia
Interventions
Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo
Behavioral · Device · Drug + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Medical Management of Sleep Disturbance During Opioid Tapering

NCT03789214
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Sleep Disturbance
Interventions
Placebo oral capsule, Low Dose Suvorexant, High Dose Suvorexant
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

NCT02491788
View directory record Official record
Conditions
Sleep Disorder, Shift-Work
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Measuring Acute Drug Demand in Humans

NCT05829655
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

Suvorexant for Treatment of AUD and PTSD

NCT06679062
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Suvorexant and Cocaine

NCT03937986
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Suvorexant, Cocaine, Placebo oral capsule
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

NCT03412591
View directory record Official record
Conditions
Sleep Disturbance, Craving, Cortisol; Hypersecretion
Interventions
Suvorexant 20 mg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Sleep/Delirium in ICU Patients

NCT04092894
View directory record Official record
Conditions
Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders, Postoperative Delirium
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

The Role of Orexin in Human Panic Disorder

NCT02593682
View directory record Official record
Conditions
Panic Disorder
Interventions
suvorexant, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Suvorexant Versus Placebo

NCT04229095
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 3, 2026, 2:16 PM EDT